Tiziana Life Sciences PLC’s (LON:TILS) (NASDAQ:TLSA) Dr Howard Weiner speaks to Proactive’s Polly Middlehurst following the news it’s submitted a patent application covering the potential use of nasally-administered and orally taken Foralumab for the treatment of COVID-19.
Dr Weiner is chairman of Tiziana’s scientific advisory board.
The methods of delivering the fully human anti-CD3 monoclonal antibody (mAb) could potentially modulate or stimulate the immune system to suppress cytokine storms and therefore reduce respiratory failure in coronavirus patients.
